The blockade of the lactate pathway through MCT4 knock-out or the inhibition of Axl in DCs sensitized LKB1 mutant tumors to immunotherapy, suggesting that combination therapies could circumvent treatment resistance in LKB1 mutant NSCLC patients. Here, STK11 is linked to non-small cell lung carcinoma.